Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

44.66 +1.68 (+3.91%)
Official Closing Price Updated: 7:00 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,395,927
Open 43.25
Bid (Size) 44.61 (9)
Ask (Size) 44.65 (4)
Prev. Close 42.98
Today's Range 43.25 - 44.78
52wk Range 39.35 - 65.38
Shares Outstanding 2,222,113,553
Dividend Yield 5.11%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... 
Via Benzinga
Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga

Performance

YTD
-15.35%
-15.35%
1 Month
+5.75%
+5.75%
3 Month
-8.84%
-8.84%
6 Month
-10.89%
-10.89%
1 Year
-31.01%
-31.01%

More News

Read More
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
Via Benzinga
A Glimpse Into The Expert Outlook On Bristol-Myers Squibb Through 4 Analysts
Via Benzinga
3 Defensive Stocks to Shield Your Portfolio in July
Via InvestorPlace
Topics Economy
Exposures Interest Rates
What the Options Market Tells Us About Bristol-Myers Squibb
Via Benzinga
High Dividend 50: Bristol-Myers Squibb
Via Talk Markets
Bristol-Myers Squibb Unusual Options Activity For July 15
Via Benzinga
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
Via Benzinga
Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity
Via Benzinga
7 Value Stocks to Buy at a 52-Week Low in July
Via InvestorPlace
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Collect $2,000 in Dividends Per Year by Investing $35,000 in These 3 Stocks
Via The Motley Fool
Topics Stocks
Exposures US Equities
US Bancorp Posts Upbeat Earnings, Joins Aehr Test Systems, Hancock Whitney And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Got $500? 2 No-Brainer Growth Stocks to Buy and Hold Forever
Via The Motley Fool
Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
Via The Motley Fool
2 Pharma Stocks to Buy Hand Over Fist This Month
Via The Motley Fool
3 Under-$10 Biotech Stocks That Could Make You Rich
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Undervalued Stocks Ready for a Breakout This Summer
Via InvestorPlace
3 Popular Stocks Trading at 52 Week Lows
Via The Motley Fool
Want $1,000 in Reliable Dividend Income? Invest $11,800 in these 3 Ultra-High-Yield Dividend Stocks.
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.